-
high content imaging, multimodality in vivo imaging, proteomics, spatial and single-cell transcriptomics. As part of King’s Health Partners, we have an excellent environment for basic-clinical
-
, a spatially-explicit agent-based model of land use change in Great Britain. This will be coupled with a system dynamics model of macro-scale drivers of land system change. Working with colleagues from
-
bronchoscopy samples and tissue. Spatial transcriptomics will be used to characterise cellular populations, functional cell states and cell- cell interactions. To validate epithelial-immune cell interactions in
-
fluorescence-lifetime detection (Fast-FLIM) and temporal focusing. This instrument will deliver quantitative, sub-second imaging of live three-dimensional cell-culture and organoid models, advancing fundamental